CD4 and melanoma: In melanoma, patients with a high TILs score (score 3 versus score 1 and 2) had a significantly lower frequency of circulating PD-L1+ CD4+ T-cells and PD-L1+ PD-1+ CD4+ T-cells (Figure S4a).